Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 3/20 | 0.48 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1617404 | 0.98 | MCL1 (0.47) | HPGDMCL1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL1616946 | 0.84 | L3MBTL1 (0.42) | MCL1L3MBTL1ALDH1A1TSHRMAPK1 | |
| SCHEMBL24512727 | 0.81 | MCL1 (0.42) | HPGDMCL1L3MBTL1ALDH1A1TSHR | |
| SCHEMBL31571089 | 0.79 | CHRNB2 (0.52) | MCL1L3MBTL1TSHRKMT2A | |
| SCHEMBL3715257 | 0.78 | MCL1 (0.33) | HPGDMCL1L3MBTL1MAPK1PREP | |
| SCHEMBL3715254 | 0.78 | MCL1 (0.33) | HPGDMCL1L3MBTL1MAPK1PREP | |
| SCHEMBL7353241 | 0.74 | MCL1 (0.58) | MCL1L3MBTL1MAPK1KMT2AHTT | |
| SCHEMBL8081259 | 0.74 | MCL1 (0.58) | MCL1L3MBTL1MAPK1KMT2AHTT | |
| SCHEMBL21477523 | 0.72 | MCL1 (0.52) | MCL1MAPK1KMT2AHTT | |
| SCHEMBL10967147 | 0.72 | MCL1 (0.56) | MCL1L3MBTL1MAPK1SMN1; SMN2KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411362-B1 | Tricyclic indole derivatives as PBR ligands | GE HEALTHCARE LTD (GB) | 2017-05-31 | — | — | EP | disclosed |
| US-9314541-B2 | In vivo imaging method for cancer | GE HEALTHCARE LIMITED (GB) | 2016-04-19 | — | — | US | disclosed |
| US-9220795-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2015-12-29 | — | — | US | disclosed |
| US-9168317-B2 | In vivo imaging method of mood disorders | GE HEALTHCARE LIMITED (GB) | 2015-10-27 | — | — | US | disclosed |
| US-20140364615-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2014-12-11 | — | — | US | disclosed |
| US-8790619-B2 | Indole derivatives | GE HEALTHCARE LIMITED (GB) | 2014-07-29 | — | — | US | disclosed |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | GE HEALTHCARE LIMITED (GB) | 2013-07-18 | — | — | US | disclosed |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | GE HEALTHCARE LIMITED (GB) | 2013-07-11 | — | — | US | disclosed |
| EP-2411362-A2 | INDOLE DERIVATIVES | GE Healthcare UK Limited (GB) | 2012-02-01 | — | — | EP | disclosed |
| US-20120020884-A1 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| WO-2010109007-A2 | INDOLE DERIVATIVES | GE HEALTHCARE LIMITED (GB) | 2010-09-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120020884-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | HPGD 2353/4885MCL1 1004/4885L3MBTL1 4359/4885 |
| US-20130183240-A1 | IN VIVO IMAGING METHOD FOR CANCER | MKI67, PBRM1, BRD4 | HPGD 308/4885MCL1 124/4885L3MBTL1 2231/4885 |
| US-20140364615-A1 | INDOLE DERIVATIVES | IDO1, IDO2, INMT | HPGD 2353/4885MCL1 1004/4885L3MBTL1 4359/4885 |
| US-20130177501-A1 | IN VIVO IMAGING METHOD OF MOOD DISORDERS | SLC18A2, SLC6A2, SLC6A4 | HPGD 239/4885MCL1 1805/4885L3MBTL1 3485/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.